UCHL1 and idiopathic pulmonary fibrosis: Although drugs targeting the ubiquitin system for the treatment of fibrosis have not yet appeared in the clinic, Panyain et al. found that potent and selective UCHL1 inhibitors blocked the pro-fibrotic response in a cellular model of IPF, which supports the potential of UCHL1 as a potential therapeutic target for fibrotic diseases 100, and fibrotic diseases are also a type of inflammatory disease, and the development of therapeutic drugs targeting the ubiquitin system in the future has been comparatively successful.